B7H6-derived peptides trigger TNF-α-dependent immunostimulatory activity of lymphocytic NK92-MI cells.

about

B7H6-derived peptides trigger TNF-α-dependent immunostimulatory activity of lymphocytic NK92-MI cells.

Item

http://www.wikidata.org/entity/Q38769013

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

B7H6-derived peptides trigger ...... of lymphocytic NK92-MI cells.

@en

type

Item

label

B7H6-derived peptides trigger ...... of lymphocytic NK92-MI cells.

@en

prefLabel

B7H6-derived peptides trigger ...... of lymphocytic NK92-MI cells.

@en

P1476

B7H6-derived peptides trigger ...... of lymphocytic NK92-MI cells.

@en

P2093

Constantine Bitsaktsis

http://www.w3.org/2001/XMLSchema#string

David Sabatino

http://www.w3.org/2001/XMLSchema#string

Francesca Romeo

http://www.w3.org/2001/XMLSchema#string

Mariana Phillips

http://www.w3.org/2001/XMLSchema#string

P2860

NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily

Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity

Cancer immunotherapy: moving beyond current vaccines

Crystal structure of human natural cytotoxicity receptor NKp30 and identification of its ligand binding site

Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells

The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer

Heat Shock Protein 70 (Hsp70) Peptide Activated Natural Killer (NK) Cells for the Treatment of Patients with Non-Small Cell Lung Cancer (NSCLC) after Radiochemotherapy (RCTx) - From Preclinical Studies to a Clinical Phase II Trial

Primer on tumor immunology and cancer immunotherapy

Trastuzumab emtansine for HER2-positive advanced breast cancer.

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

P304

658-672

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/BIP.22879

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27216712

http://www.w3.org/2001/XMLSchema#string